Korro Bio (KRRO) Cash & Current Investments (2018 - 2026)

Korro Bio (KRRO) has 9 years of Cash & Current Investments data on file, last reported at $114.0 million in Q1 2026.

• Quarterly Cash & Current Investments fell 0.86% year-over-year to $114.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.0 million (down 0.86% YoY) and the FY2025 annual result came in at $75.2 million, down 40.4% from the prior year.
• Cash & Current Investments grew to $114.0 million in Q1 2026, from $75.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $169.8 million in Q4 2023 to a low of $36.9 million in Q4 2022.
• A 5-year average of $102.7 million and a median of $111.0 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 71.74% — and 2023, when it surged 359.62%.
• Tracing KRRO's Cash & Current Investments over 5 years: stood at $36.9 million in 2022, then surged by 359.62% to $169.8 million in 2023, then declined by 25.72% to $126.1 million in 2024, then sank by 40.4% to $75.2 million in 2025, then surged by 51.64% to $114.0 million in 2026.
• The last three Cash & Current Investments figures came in at $114.0 million (Q1 2026), $75.2 million (Q4 2025), and $92.5 million (Q3 2025), per Business Quant data.